Price movement over the last 24 hours
Enact Holdings Inc vs Cronos Group Inc — how do they compare? Enact Holdings Inc trades at $45.22 (market cap $6.35B), while Cronos Group Inc trades at $2.75 (market cap $1.03B). The key difference: Enact Holdings Inc is far larger — about 6.2× Cronos Group Inc's market cap, and Enact Holdings Inc pays a 1.91% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| ACT | CRON | |
|---|---|---|
Market Cap | $6.35B | $1.03B |
Sector | Technology | Health |
52-Week High | $45.71 | $3.27 |
52-Week Low | $34.39 | $1.95 |
Enterprise Value | $6.55B | $205.93M |
Dividend Yield | 1.91% | — |
Signals from Pluang's Aura AI — not financial advice
ACT trades at $45.69, up 0.77% today, with a bullish technical signal and strong moving averages. The stock shows robust fundamentals with a net income margin of 54.49% and a P/E ratio of 9.89. Recent news includes a 14% dividend increase announced on May 5, 2026, and Q1 2026 earnings that met expectations. Analyst consensus is a $47.50 price target with a mix of buy and hold ratings.
Outlook remains positive due to high profitability and dividend growth, but risks include earnings volatility and market sensitivity. Upside is supported by institutional sentiment and consistent cash flow, though investors should monitor execution against future earnings estimates.
Cronos Group (CRON) trades at $2.75, down 3.85% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 revenue growth of 40% year-over-year to $45.2 million, achieving record net revenue and gross profit. However, net income remains negative at -$9.45 million for 2025, though margins have improved significantly from prior years. Recent news highlights expansion in Canada and Israel, along with a share repurchase program extension.
Outlook is cautiously optimistic with strong revenue growth and market share gains, but profitability challenges and intense cannabis competition pose risks. Analyst sentiment is mixed with 60% hold ratings. Key catalysts include international expansion and execution on cost controls, while regulatory uncertainty and cash flow volatility remain headwinds for investors.
Trailing returns across standard periods
Latest headlines on both assets
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →